» Articles » PMID: 28250159

Antigen Density Dictates Immune Responsiveness Following Red Blood Cell Transfusion

Abstract

Although RBC transfusion can result in the development of anti-RBC alloantibodies that increase the probability of life-threatening hemolytic transfusion reactions, not all patients generate anti-RBC alloantibodies. However, the factors that regulate immune responsiveness to RBC transfusion remain incompletely understood. One variable that may influence alloantibody formation is RBC alloantigen density. RBC alloantigens exist at different densities on the RBC surface and likewise exhibit distinct propensities to induce RBC alloantibody formation. However, although distinct alloantigens reside on the RBC surface at different levels, most alloantigens also represent completely different structures, making it difficult to separate the potential impact of differences in Ag density from other alloantigen features that may also influence RBC alloimmunization. To address this, we generated RBCs that stably express the same Ag at different levels. Although exposure to RBCs with higher Ag levels induces a robust Ab response, RBCs bearing low Ag levels fail to induce RBC alloantibodies. However, exposure to low Ag-density RBCs is not without consequence, because recipients subsequently develop Ag-specific tolerance. Low Ag-density RBC-induced tolerance protects higher Ag-density RBCs from immune-mediated clearance, is Ag specific, and occurs through the induction of B cell unresponsiveness. These results demonstrate that Ag density can potently impact immune outcomes following RBC transfusion and suggest that RBCs with altered Ag levels may provide a unique tool to induce Ag-specific tolerance.

Citing Articles

Clinical Characteristics and Prognosis of Hemolytic Disease of the Newborn Caused by Irregular Antibodies: A 13-Year Retrospective Analysis.

Wu H, Li R, Wei H, Zhu W, Xing Y Children (Basel). 2025; 11(12.

PMID: 39767838 PMC: 11674851. DOI: 10.3390/children11121409.


Dynamics of antibody engagement of red blood cells and .

Jajosky R, Ayona D, Mener A, Stowell S, Arthur C Front Immunol. 2024; 15:1475470.

PMID: 39669570 PMC: 11634868. DOI: 10.3389/fimmu.2024.1475470.


ABO blood groups and galectins: Implications in transfusion medicine and innate immunity.

Arthur C, Hollenhorst M, Wu S, Jajosky R, Nakahara H, Jan H Semin Immunol. 2024; 74-75:101892.

PMID: 39405833 PMC: 11808837. DOI: 10.1016/j.smim.2024.101892.


Harnessing the potential of red blood cells in immunotherapy.

Jajosky R, Zerra P, Chonat S, Stowell S, Arthur C Hum Immunol. 2024; 85(6):111084.

PMID: 39255557 PMC: 11808826. DOI: 10.1016/j.humimm.2024.111084.


Complement C3 and marginal zone B cells promote IgG-mediated enhancement of RBC alloimmunization in mice.

Jash A, Pridmore T, Collins J, Hay A, Hudson K, Luckey C J Clin Invest. 2024; 134(8).

PMID: 38618959 PMC: 11014669. DOI: 10.1172/JCI167665.


References
1.
Brantley S, Ramsey G . Red cell alloimmunization in multitransfused HLA-typed patients. Transfusion. 1988; 28(5):463-6. DOI: 10.1046/j.1537-2995.1988.28588337338.x. View

2.
Ryder A, Zimring J, Hendrickson J . Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models. Transfus Med Hemother. 2015; 41(6):406-19. PMC: 4280453. DOI: 10.1159/000368995. View

3.
Bussel J, Berkowitz R, McFarland J, Lynch L, Chitkara U . Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med. 1988; 319(21):1374-8. DOI: 10.1056/NEJM198811243192103. View

4.
Reali G . Forty years of anti-D immunoprophylaxis. Blood Transfus. 2009; 5(1):3-6. PMC: 2535875. DOI: 10.2450/2007.0b18-06. View

5.
Gauld S, Dal Porto J, Cambier J . B cell antigen receptor signaling: roles in cell development and disease. Science. 2002; 296(5573):1641-2. DOI: 10.1126/science.1071546. View